Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.

NCT06332430 is registered in ClinicalTrials.gov with Canwell Biotech Limited as lead sponsor.

NCT NCT06332430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06332430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.
Lead sponsor
Canwell Biotech Limited
Phase
Phase 1
Overall status
Recruiting
Start date
May 28, 2024
Completion date
May 30, 2026
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumor